BioCryst Pharmaceuticals, Inc. BCRX
NASDAQ · United States · Health Technology
$8.33+0.06 (+0.73%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic’s Claude AI recently sold its positions in Ardelyx Inc. (NASDAQ: ARDX) and Aris Mining Corp. (NYSE: ARIS) and replaced them with Syndax Pharmaceuticals Inc. […]
Beneath the headline-driven sentiment of biotech investing lies the true engine of value creation: portfolio durability, capital efficiency, and sustainable revenue compounding. Founded on the promise of structure-based drug design, BioCryst Pharmaceuticals (NASDAQ:BCRX) has evolved from a speculative research shop into a commercial-stage rare disease specialist. The company’s core operational drivers now center on maximizing […]
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
BCRX is flashing a historically bullish signal
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.